Biocom’s top priority is the safety of our members and the well-being of our employees. After careful consideration, Biocom has decided to transform our 2021 Global Life Science Partnering Conference to a fully virtual event. We know that many lives are being impacted and disrupted by COVID-19 and we are grateful to be able to continue offering our members valuable content in a safe manner.
General Partner, Lilly Ventures
Armen Shanafelt is a General Partner at Lilly Ventures. Prior to joining Lilly Ventures in 2009, he had over 24 years of experience in the pharmaceutical, biotechnology, and diagnostic businesses. Armen serves as a director on the boards of Aeglea Biotherapeutics (AGLE), Aileron Therapeutics (ALRN), Protagonist Therapeutics (PTGX), Sutro Biopharma, Surface Oncology and Symic Bio. He is a Kauffman Fellow (Class 14).
He received his B.S. Degree in Chemistry and Physics from Pacific Lutheran University and his Ph.D. in Chemistry from the University of California, Berkeley, and completed his postdoctoral work at DNAX Research Institute.